Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Stopped early · Phase 1

Conditions studied: Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

In brief

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

Key facts

Study ID

NCT02244489

Run by

Sierra Oncology LLC - a GSK company

People needed

16

Starts

2014-11-05

Expected to finish

2017-04-05

Last updated by the study team

2019-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Scottsdale Healthcare Research Institute — Scottsdale, Arizona, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.